VERA Stock: Price, Earnings History and SEC Filings
Vera Therapeutics, Inc. (VERA) last traded at $30.98, up 1.47% on the latest session and down 4.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.52 against an analyst estimate of $-1.60, a beat of 5.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VERA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-1.52 | $-1.60 | +5.00% |
| Mar 2026 | May 7, 2026 | $-1.69 | $-1.26 | -34.13% |
| Dec 2025 | Feb 26, 2026 | $-1.39 | $-1.34 | -3.73% |
| Sep 2025 | Nov 5, 2025 | $-1.26 | $-1.20 | -5.00% |
VERA beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How VERA reacts to earnings
Across its last 8 earnings releases, VERA moved 3.5% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | After close | -4.08% |
| 2026-05-07 | Before open | -1.95% |
| 2026-02-26 | Before open | +1.61% |
| 2025-11-05 | Before open | -1.03% |
| 2025-08-05 | Before open | +0.93% |
| 2025-05-06 | Before open | -13.79% |
| 2025-02-26 | Before open | +2.47% |
| 2024-11-07 | Before open | +2.29% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VERA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$300M | -$242M | – | $-4.66 |
| 2024 | – | -$152M | -$136M | – | $-2.75 |
| 2023 | – | -$96M | -$92M | – | $-2.25 |
| 2022 | – | -$89M | -$68M | – | $-3.35 |
| 2021 | – | -$33M | -$24M | – | $-2.43 |
| 2020 | – | -$53M | -$35M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VERA
- 8-K · Sep 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 9, 2026Officer or director change
- 8-K · Jul 7, 2026Other events
- 8-K · Jun 2, 2026Other events
- 8-K · May 26, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 9, 2026
Insider filing activity
VERA insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VERA news
- Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsOct 23, 2026 · marketbeat.com
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineOct 22, 2026 · finance.yahoo.com
- Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastOct 20, 2026 · finance.yahoo.com
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. (VERA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.